NovaBay Pharmaceuticals (NBY) Reports In-Line with Strong Guidance, PT Lowered to $4 at Ascendiant Capital
Tweet Send to a Friend
Ascendiant Capital analyst Edward Woo lowered the price target on NovaBay Pharmaceuticals (NYSE: NBY) to $4.00 (from $4.25) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
